KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Net Income (2016 - 2024)

Historic Net Income for Travere Therapeutics (TVTX) over the last 16 years, with Q4 2024 value amounting to $4000.0.

  • Travere Therapeutics' Net Income rose 10025.36% to $4000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $4000.0, marking a year-over-year increase of 10015.77%. This contributed to the annual value of -$915000.0 for FY2024, which is 10034.54% down from last year.
  • As of Q4 2024, Travere Therapeutics' Net Income stood at $4000.0, which was up 10025.36% from -$100000.0 recorded in Q3 2024.
  • Over the past 5 years, Travere Therapeutics' Net Income peaked at $240.0 million during Q3 2023, and registered a low of -$121.6 million during Q4 2020.
  • For the 5-year period, Travere Therapeutics' Net Income averaged around -$3.5 million, with its median value being -$101500.0 (2024).
  • As far as peak fluctuations go, Travere Therapeutics' Net Income crashed by 657439.9% in 2021, and later skyrocketed by 156569.03% in 2023.
  • Quarter analysis of 5 years shows Travere Therapeutics' Net Income stood at -$121.6 million in 2020, then rose by 27.01% to -$88.8 million in 2021, then surged by 122.32% to $19.8 million in 2022, then plummeted by 107.96% to -$1.6 million in 2023, then surged by 100.25% to $4000.0 in 2024.
  • Its Net Income stands at $4000.0 for Q4 2024, versus -$100000.0 for Q3 2024 and -$757000.0 for Q2 2024.